Adma Biologics (ADMA) Cash from Financing Activities (2011 - 2025)

Adma Biologics has reported Cash from Financing Activities for 13 years, with the latest figure at -$9.1 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities rose 70.61% year-over-year to -$9.1 million; the trailing twelve-month figure through Dec 2025 stood at -$44.0 million (up 24.49% YoY), and the FY2025 full-year result was -$44.0 million, up 24.49% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at -$9.1 million, up from -$27.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $62.7 million in Q4 2022, with the low at -$39.0 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged $4.4 million across 5 years, with a median of -$340520.5 in 2022.
• Annual changes were most pronounced in 2021 — Cash from Financing Activities jumped 1014330.22% — and 2024, when it sank 6221.88%.
• Adma Biologics' Cash from Financing Activities stood at $53.8 million in 2021, then gained by 16.58% to $62.7 million in 2022, then plunged by 162.15% to -$39.0 million in 2023, then climbed by 20.44% to -$31.0 million in 2024, then soared by 70.61% to -$9.1 million in 2025.
• The last three Cash from Financing Activities figures came in at -$9.1 million (Q4 2025), -$27.8 million (Q3 2025), and $48000.0 (Q2 2025), per Business Quant data.